Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02974153 · ClinicalTrials.gov registry record · Phase 3
Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine
A Phase 3 study, sponsored by Alder Biopharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,121
- Enrollment target
NCT02974153 is a Phase 3 study that has completed, run by Alder Biopharmaceuticals. The registered enrollment target is 1,121 participants.
The verdict
NCT02974153, a Phase 3 study, has completed, sponsored by Alder Biopharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,121 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL ALD403 (Eptinezumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,121 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02974153
The ClinicalTrials.gov registry entry for NCT02974153 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,121 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alder Biopharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02974153 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02974153 about?
NCT02974153 is a clinical study titled "Evaluation of ALD403 (Eptinezumab) in the Prevention of Chronic Migraine". The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.
What is the current status of trial NCT02974153?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,121 participants. The study started on 2016-11. Estimated completion is 2018-04.
What interventions are being tested in trial NCT02974153?
The interventions under investigation include: Placebo (BIOLOGICAL), ALD403 (Eptinezumab) (BIOLOGICAL).
Who is sponsoring clinical trial NCT02974153?
This trial is sponsored by Alder Biopharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.